Business Context and Reporting Period
Company: Modular Medical, Inc. (MODD)
Filing Type: Form 8-K (Current Report)
Date of Report: August 22, 2024
Principal Business: Development of the MODD-1 insulin pump product.
Reporting Period: This filing reports on specific corporate events occurring on August 22, 2024, and the cancellation of prior milestones on August 2, 2024.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, or debt metrics. The filing focuses exclusively on equity compensation arrangements and milestone achievements.
Material Changes and Events
- Cancellation of Prior Milestone Options: On August 2, 2024, options granted under the "Milestone 2" of the 2023 Bonus Program were canceled because the Company did not receive FDA clearance notification for the MODD-1 by the August 1, 2024 deadline.
- New Executive Option Grants: On August 22, 2024, the Board granted new stock options to executive officers with an exercise price of $1.71 per share (closing price on grant date):
- Paul DiPerna (Chairman, President, CFO, Treasurer): 58,560 options.
- Kevin Schmid (COO): 24,400 options.
- New Non-Executive Option Grants: The Board approved options for an aggregate of 256,338 shares for certain non-executive employees.
- Vesting Conditions: All new options granted on August 22, 2024, are contingent on the Company receiving FDA clearance notification on or before December 31, 2024. If this condition is not met, the options will not vest and will terminate on January 1, 2025.
Outlook, Risks, and Contingencies
Primary Contingency: The vesting of all new equity grants announced in this filing is strictly dependent on the receipt of FDA clearance notification for the MODD-1 product by December 31, 2024.
Risk Factor: Failure to achieve FDA clearance by the new deadline will result in the forfeiture of the newly granted options for both executive and non-executive employees, representing a significant potential loss of employee incentive value.
Key Facts for Investor Verification
- Verify the current status of the MODD-1 FDA 510(k) submission and any recent communications from the FDA.
- Confirm the December 31, 2024 deadline for FDA clearance notification as the sole condition for the vesting of the new 2024 option grants.
- Note the increase in the exercise price for new executive options from $1.11 (2023 grant) to $1.71 (2024 grant).
- Review the total number of shares subject to the new non-executive grants (256,338) to assess potential dilution if the milestone is achieved.